Medical Testing Services and Consulting

Your partner for accurate health testing within assisted living, skilled nursing, and retirement communities.

CALL US TODAY

Medical Testing Services and Consulting

Your partner for accurate health testing within assisted living, skilled nursing, and retirement communities.

CALL US TODAY

About Us

Our Story

At MedIcal Testing, Services and Consulting we started with a simple goal: To provide affordable and accessible testing services to everyone within assisted living, skilled nursing, and retirement communities.. Partnering with a number of select laboratories, we are a trusted provider of high-quality testing services, with a team of experienced professionals dedicated to providing the best possible care to our clients.

Our services include, but are not limited to, PCR Testing, PGX Testing, Genetics Testing, Molecular Testing, Toxicology Testing, General Health Testing, and Next-Generation Sequencing.

At MTSC you receive preventive health screenings to detect small problems before they turn into big ones. When your doctor catches a problem early, treatment options may be more effective, less invasive, and less expensive.

John Parker, Founder & Chief Executive Officer

Founder & CEO John Parker is a forward thinking leader who understand the need to take care of our senior population. He has realized that by 2030 more people in the United States will be older than age sixty-five than younger than age five.He understands that our health care system is unprepared for the complexity of caring for a heterogenous population of older adults—a problem that was magnified by the coronavirus pandemic.

Parker knows all to well that preventive health screenings are a smart way to safeguard your overall health and well-being. He knows that these forward thinking health screenings offer a wide range of benefits, such as catching potential health issues early, preventing more severe problems from developing, improving your overall quality of life, and reducing healthcare costs. Plus, by finding out your risk factors for specific conditions, people have the opportunity to make lifestyle changes to lower their risk.

John Parker believes that making preventive health screenings a priority is your best bet for continued good health.

OUR PROGRAM

Traditional testing programs charge thousands of dollars to test for a single disease, and at most, up to 30 diseases. These expensive tests often only scratch the surface of your genes, leaving a wealth of crucial information untouched.

MTSC is here to change that narrative.

Our program focuses on leveraging advanced genetic testing technology to identify pathogens swiftly, enabling proactive measures to mitigate disease spread and reduce morbidity and mortality rates among residents. Partnering with reputable labs across the United States, we offer comprehensive testing for over 52 different pathogens, including respiratory, urinary tract, wound, and gastrointestinal pathogens, utilizing state-of-the-art PCR/PGX technology.

In addition to pathogen identification, our testing also identifies patients predisposed to certain diseases such as cancer, dementia, Alzheimer's, Parkinson's, sudden cardiac death, pulmonary embolism, COPD, rheumatoid arthritis, lupus, psoriatic arthritis, narrow and wide-angled glaucoma, cataracts, and numerous other life-threatening conditions just to name a few. By providing early detection and intervention, our program aims to optimize patient care outcomes and reduce hospital admissions.

Furthermore, we offer genetic testing to identify predispositions to specific diseases, facilitating early screening and tailored preventative and palliative care. Importantly, all testing services are covered by Medicare and Medicaid, ensuring accessibility and affordability for patients.

Our team includes medical professionals with years of experience in the testing industry. We are committed to providing our clients with the highest level of care and attention, and we work tirelessly to ensure that our testing services are accurate, reliable, and affordable.

WHAT WE OFFER: Genetic Variant Testing by NGS

Cardiomyopathy NGS Panel designed to detect multiple cardiomyopathy conditions.

Cancer Genetic Testing (CGx) NGS Panel to understand your patients' risk factors for cancer using th

Cardiomyopathy NGS Panel designed to detect multiple cardiomyopathy conditions.

Cardiomyopathies are a group of diseases in the heart muscle associated with mechanical and/or electrical dysfunction. Comprehensive testing allows for the evaluation of multiple cardiomyopathy conditions.

Cardiomyopathies are a broad classification of diseases that include diseases with genetic origins, acquired and mixed (both genetic and non-genetic).1 However, a significant percentage of cardiomyopathies are inheritable diseases and are a major cause or morbidity and mortality.2

Hypertrophic Cardiomyopathy (HCM)
Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVD)
LV Noncompaction (LVNC)
Dilated Cardiomyopathy

Diagnostic testing for various Cardiomyopathy diseases may help establish a diagnosis, inform management, and clarify risks.

Eye Disorder NGS Panel

To identify genes and variants in various eye diseases.

The eye disorder panels consist of multiple panels for various eye disorders including, but not limited to: retinal disorders, optic nerve disorders, corneal diseases, structural diseases, eye movement diseases, glaucoma, cataract, and myopia. Combined, these panels analyze 81 genes.

Panels for inherited retinal diseases include both syndromic and non-syndromic retinal diseases. A majority of retinal diseases are non-syndromic and limited to an ocular phenotype. However, a minority of retinal diseases are syndromic and have a border phenotype involving multiple organ systems.

Panels for syndromic retinal diseases include: Usher Syndrome, Joubert Syndrome, Senior-Loken Syndrome, Stickler Syndrome, and Bardet-Biedl Syndrome.

Panels for non-syndromic retinal disorders include: Retinitis Pigmentosa, Leber Congenital Amaurosis, Macular Dystrophy, Stargardt Disease, Cone-rod Dystrophy, Exudative Vitreoretinopathy, and Achromatopsia.

Identifying the genes and variants involved in various eye diseases can assist in clinical management. In addition, identifying targeted therapies may reduce risk of disease occurrence and recurrence in families at risk, can improve accuracy of genetic counseling, and may have a positive impact on individuals and families. In many eye diseases, different mutations in the same gene may result in different clinical presentations. In addition, different genes may be associated with a spectrum of variations in disease onset, progression, severity of vision loss and phenotypes can vary among family members.

Pharmacogenetic (PGx) NGS Panel

In order to better understanding of how patients will respond to medications.

Genetics account for 20–90% of variability in drug disposition and effects. The rate of drug metabolism varies between individuals. People can be poor, intermediate, extensive or rapid metabolizers of drugs based on their genotype for CYP 450 family of enzymes. CYP 450 family of enzymes metabolize drugs to active or inactive metabolites. People who are poor or rapid metabolizers are prone to drug toxicity or lower effectiveness of drugs.

Our simple pharmacogenetic testing service, PGx Testing, uses a patient’s genes to determine how they will respond to a particular medicine or a combination of medicines and identifies their unique sensitivities to possible drug effects. As a result, healthcare providers can minimize or completely avoid trial-and-error dosing and substantially reduce the risk of potential adverse drug events.

770,000 injuries and deaths annually in the United States are tied to adverse drug reactions.

Thyroid Genetics NGS Panel

In order to discovering genetic changes in your thyroid.

There are around 600,000 people in the United States annually that undergo a fine-needle aspiration (FNA) biopsy to examine thyroid nodules. During these biopsies, cells are extracted and tested to determine cellular condition (whether they are benign or cancerous) using microscopy/cytology-based methods.

Although accurate, 20%-25% of FNA biopsies are returned with an indeterminate result. Most patients undergo diagnostic surgery, with approximately 60% being overtreated or undertreated. Because of this, microscopical observations of cells from nodules and surgical removal are not the most optimal treatment options for patients.

Today, management of thyroid nodules has expanded to molecular genetic testing, using next generation sequencing (NGS) technology. Highly-sensitive NGS technology determines genetic changes in thyroid nodules, resulting in informative risk assessment and avoidance of unnecessary surgeries.

Our Thyroid Genetics Test examines genetic changes that are relevant for hypothyroidism, thyroid hormone resistance, and thyroid risk panel. This NGS panel consists of 45 genes. These are listed in the table along with the disease-related conditions.

Cardiopulmonary NGS Panel for early diagnosis to improve long-term health.

Cancer Genetic Testing (CGx) NGS Panel to understand your patients' risk factors for cancer using th

Cardiomyopathy NGS Panel designed to detect multiple cardiomyopathy conditions.

Cardiopulmonary syndromes are conditions of the heart and lung. These organs are closely connected, and a problem in one can spill over to the other.

For example, when the heart is not able to pump blood efficiently, normal oxygen movement in the lungs is reduced, causing shortness of breath. On the other hand, a problem with the lungs can cause the heart to work harder to get oxygen from the lungs into the blood.

The Cardiopulmonary NGS panel includes 236 genes and covers a wide variety of diseases affecting the heart and lungs. Benefits of genetic testing include:

Earlier diagnosis, leading to earlier initiation of preventative therapies and improving long-term cardiopulmonary health.
Many cardiopulmonary diseases have associated complications that can be treated effectively, if detected early.
A firm diagnosis can direct patients to appropriate experimental therapies or clinical trials.

Hereditary Neurodegenerative Disease NGS Panel

To detect risk factor genes associated with neurodegenerative disorders.

An accurate, timely diagnosis of a nonreversible decline in mental function is crucial to ensure a personalized and data-driven treatment plan is provided to the patient. Early-stage support can help avoid unnecessary struggles and expenses associated with missed treatment opportunities.

MTSC offers our Hereditary Neurodegenerative panel, which examines 161 genes associated with an increased risk of developing neurodegenerative disorders and detects both the diagnostic and risk factor genes for Dementia, Alzheimer's, Parkinson's, and more.

Dementia

Dementia is a relatively common disease in people over the age of 60 with a prevalence of 5-7%.1 Dementia consists of cognitive and behavioral symptoms that interfere with usual activities and represent a decline from previous function.2 Many forms of dementia are thought to be multifactorial and are genetically complex diseases; however, some have been shown to be due to distinct genetic causes.

Alzheimer's Disease

Alzheimer’s is the most common type of dementia and typically begins with a subtle failure of memory that progresses over time until it becomes incapacitating. Approximately 25% of all Alzheimer’s is familial, discovered through family history and molecular genetic testing. Less than 10% of Alzheimer's disease is early-onset and is likely an inherited disease. Three genes have been linked to early-onset Alzheimer's disease, accounting for a majority of cases: APP, PSEN1, PSEN2.4 5 3

Frontotemporal Dementia (FTD)

In contrast to Alzheimer’s disease, FTD is more frequently seen in patients younger than 65 and may present as changes in behavior and personality or as language difficulties.6 Up to 40% have a family history of FTD. Autosomal dominant mode of inheritance has been identified in 10% of patients.

Parkinson's Disease

The second most common neurodegenerative disease, and has prevalence in approximately 1% of people over the age of 60. It typically consists of motor features such as tremor and muscle rigidity, but can also include cognitive decline and dementia.8 Causes can be genetic and environmental, but 5-10% of patients have a monogenic form caused by mutations in a specific gene.

Pulmonary NGS Panel

For early diagnosis to help preserve lung function.

Pulmonary diseases, also known as lung disorders and respiratory diseases, affect the lung and other parts of the respiratory system. Pulmonary diseases may be caused by infection, breathing in tobacco smoke or other forms of air pollution, or genetic variations, which are associated with inherited/genetic pulmonary diseases.

The most common genetic respiratory disease is cystic fibrosis, which affects the airways. Other examples of genetic pulmonary diseases include primary ciliary dyskinesia, tuberous sclerosis, Birt-Hogg-Dube syndrome, among many others.

Benefits of Genetic Testing Include:

Many genetic lung diseases have associated complications involving other organs that can be treated effectively, if detected early.
A firm diagnosis can direct patients to appropriate experimental therapies or clinical trials.
Early diagnosis is important for preserving lung function. Once a diagnosis of any type of rare lung disease is confirmed, patients will be closely monitored for the development of complications including lung infection, pneumothorax (collapsed lung), or end-stage lung disease. Earlier diagnosis, leading to earlier
initiation of preventative therapies can improve long-term lung health.

Cancer Genetic Testing (CGx) NGS Panel to understand your patients' risk factors for cancer using th

MTSC targets the most important genes associated with breast, colon, pancreatic, gynecological and melanoma cancers. These tests are ordered frequently by oncologists, as well as family doctors and internal medicine doctors that are primary care physicians and with patients with at-risk family histories.

Inherited Gene Mutations

MTSC offers a multi-gene panel that accurately identifies the presence of an inherited gene mutation or alteration. A patient who receives a negative test result will benefit from peace of mind knowing they did not inherit a harmful gene variant, while a patient who receives a positive test result will benefit from opportunities to better understand and potentially manage their cancer risk, and to make important decisions about their medical care.

In addition to determining an increased risk for developing cancer, our blood panel also points to types of cancer screenings that should be conducted.

While many inherited genetic variants are beneficial or neutral, others are harmful and believed to contribute to 5-10% of all cancers.

Breast and Ovarian Cancer

BRCA genes come in pairs (BRCA1 and BRCA2). Only one gene in the pair needs to have a mutation to put a patient at risk for cancer. For women, a BRCA mutation increases the risk for breast and ovarian cancers. For men, the overall risk for cancer is lower than women, although the risk for breast, prostate and skin cancers is increased.

Lynch Syndrome

Inherited mutations in the genes of MLH1, MSH2, MSH6, PMS2 and EPCAM give a patient an increased lifetime risk of certain cancers. This genetic syndrome, known as Lynch syndrome and also called hereditary non-polyposis colorectal cancer (HNPCC), puts patients at a higher risk of certain types of cancer.

Who and Why to Test

The American Cancer Society has outlined certain factors associated with cancers that run in families. Physicians should consider CGx testing for any patient who has one or more of these family histories.

Multiple cases of the same type of cancer, particularly if it is a rare or uncommon type of cancer
Cancers occurring at younger-than-usual ages, such as colorectal cancer in a 22-year-old
More than one type of cancer occurring in one family member, such as a female with both breast and ovarian cancer
Cancers occurring in both of a pair of organs, such as both breasts, both kidneys, both eyes, both ovaries
Cancer occurring in a gender not usually affected, such as breast cancer in a male relative
Cancer occurring across generations, such as grandmother, mother and daughter, or grandfather, father and son
Childhood cancer occurring in more than one sibling, such as sarcoma in both a sister and brother

Primary Immunodeficiency NGS Panel

In order to distinguish diseases with overlapping symptoms.

Autoimmune diseases affect 3-10% of the population.1 However, prevalence varies greatly between different diseases, as well as incidence of the same disease among different demographics.

Primary immunodeficiencies (PIDs) are inherited diseases associated with a considerable increase in susceptibility to infections. It is known that PIDs can also predispose patients to cancer and immune diseases, including allergy, autoimmunity, and inflammation.

Autoimmune diseases involve activation of the adaptive immune system against self-antigens. They are a diverse group of disorders. Some are organ specific while others are systematic and affect multiple organ systems. The majority of autoimmune diseases involve multiple factors, both genetic and environmental. However, a minority of autoimmune diseases are monogenic and associated with a specific genetic cause.

This gene panel helps in the diagnosis of autoimmune diseases, and in complex clinical cases, helps distinguish between diseases with overlapping symptoms to aid in risk assessment. This panel tests for diseases including HIV, Pneumocystosis, Nezelof’s Syndrome, Pancytopenia, Myelofibrosis, and more.

Cancer Genetic Testing (CGx) NGS Panel to understand your patients' risk factors for cancer using th

Infectious Diseases Testing services

Respiratory Pathogen PCR Panel (RPP)

Sexually Transmitted Infection (STI) PCR Panel

Accurately detect seasonal bacteria and viruses.

Medical Testing Services and Consultants offers highly utilized RPP testing that detects 53 respiratory pathogens, now including COVID-19, and 43 antibiotic resistance markers — and we do so with a robust 24-hour validation.

Sensitivity and Specificity

Family doctors, internal medicine physicians and pediatricians frequently order our infectious diseases tests for bacteria and viruses causes of infection in the upper respiratory and lower respiratory (pneumonia microorganisms). Unlike rapid assays commonly performed in clinics and doctors’ offices, our panel is inordinately more sensitive, more specific and does not rely on a healthcare provider’s assumptions or knowledge about the seasonality of viruses.

As a result of the expeditious accuracy of MTSC's molecular respiratory pathogen testing, physicians and patients alike realize a range of important benefits.

Reduce false negatives
Detect polymicrobial infections
Include one of the most extensive antibiotic resistance gene panels
Are unaffected by concurrent antibiotic use
Reports consistently delivered within 24 hours

Specific, Accurate Diagnoses

53 Pathogens and 43 antibiotic resistance markers associated with acute respiratory disease can be detected including COVID-19, Coronavirus HKU, Coronavirus NL63, Coronavirus 229E, and Coronavirus OC43.
Flu, one of the most severe illnesses of the winter season, is identified and diagnosed through the use of various target gene assays.
Respiratory Syncytial Virus (RSV), the most common viral cause of death in children younger than five years, is diagnosed through tests based on reverse transcription- polymerase chain reaction.
Pneumonia, the most common cause for adult hospital admissions, has a highly improved diagnosis rate as a result of our techniques and transcription for specific, more sensitive systems of pathogen detection.

Common Misdiagnoses of Influenza

According to the Center for Disease Control, most of the rapid influenza diagnostic tests that can be conducted in a physician’s office are only 50-70% accurate.

Sexually Transmitted Infection (STI) PCR Panel

Accurately detects all STI pathogens including antibiotic-resistant gene identification.

Centers for Disease Control and Prevention shows that 1 in 5 people had a sexually transmitted infection (STI) on any given day in 2018 in the United States. According to 2018 CDC’s report: 26 million new STI cases were found in 2018 alone and ~50% of these infections affected people between the ages of 15-24, at a cost of nearly $16 billion medical cost.

Fast and Accurate Laboratory Testing

MTSC offers STI molecular diagnostics that provide the highest sensitivity and specificity:

Accurately detects all STI pathogens (please see the STI requisition), including antibiotic-resistant gene identification such as vancomycin and methicillin-resistance.
Shortens the time of pathogenic diagnosis and effective treatment of STIs.
Robust 24-hour turnaround time with advanced molecular genetic tests (PCR).
Innovative molecular technology has superior sensitivity vs. microbiology-based testing.
User-friendly reporting provides clear antibiotic guidance for effective treatment and improved patient outcomes.

Did you know...

According to the DHHS, some STIs aren't curable, but their identification can help prevent transmission and help clinicians prescribe medicine to treat the symptoms.

Molecular Onychomycosis Nail Fungus PCR Testing

Take the guesswork out of treating fungal infections.

Fungi can infect almost any part of the body; however, these infections are most commonly observed in the skin and nails, mainly in the foot. Anyone can acquire these infections, but the elderly and critically ill are often the most common sufferers.

Our nucleic acid-based amplification test (NAAT) utilizes semi-quantitative real-time polymerase chain reaction (RT-PCR) technology to help clinicians identify the fungal and bacterial pathogens found in nail tissue, enabling doctors to begin targeted therapy within days.

Our RT-PCR assay can accurately identify unique nucleic acid segments of each pathologic fungi or bacteria at genus and some at species level. Our test is performed using the patient’s nail clippings, and multiple pathogens can be detected in one test.

Urinary Tract Infection (UTI) PCR Panel

Sexually Transmitted Infection (STI) PCR Panel

Urinary Tract Infection (UTI) PCR Panel

Antibiotic resistance, greater sensitivity and specificity with 24-hour turnaround.*

Fast and Accurate

MTSC introduces UTI Testing for clinicians who want fast results and greater understanding of their patient’s health. Unlike conventional urine culture tests, MTSC’s UTI molecular diagnostics offers the highest sensitivity and specificity as well as the detection of antibiotic resistance with results reported in 24 hours after the sample is received at the lab.

Molecular UTI detects slow-growing, difficult-to-cultivate microorganisms, making it ideal for when culture methods are inadequate, ambiguous, time-consuming, difficult, and costly.

The MTSC Advantage

Fast:

Results within 24 hours after being received in the lab.

Accurate:

Detects 49 different pathogens and 43 markers
Detects slow-growing, difficult-to-cultivate microorganisms

Reliable:

MTSC is recognized as one of the most reliable labs in the U.S.

Wound Pathogen PCR Panel

Take the guesswork out in diagnosing and treating wound pathogens.

Our wound pathogen assay utilizes the nucleic acid-based amplification test (NAAT) with the latest in semi-quantitative real-time polymerase chain reaction (RT-PCR) technology to rapidly and reliably analyze your patient’s sample. PCR provides the greatest sensitivity and specificity with the ability to rapidly detect and differentiate 98-99% of the most common aerobic, anaerobic, and facultative bacteria, viral and fungal targets, and polymicrobial infections.

Our universal sample collection medium eliminates the need for specialized live sample handling or storage by safely inactivating and stabilizing the sample in transport for subsequent analysis. This reduces the impact of transport time and cost.

Use the latest in molecular diagnostic technology to diagnose wounds that are slow to heal including:

Diabetic ulcers
Pressure sores
Venous ulcers

Toxicology Testing services

Prescription Medication Monitoring (PMM)

Manage employees and treatments alike with extensive toxicology testing.

MTSC’s industry-leading clinical toxicology testing of urine, saliva and blood provide accurate and critical information for physicians to verify patients’ drug usage compliance, adjust treatment or terminate drug therapy to protect patients from harm, and prevent prescribing physicians from legal issues.

An Extensive Panel Test for Prescription Drug Pain Management

Our more than 70 analytes drug confirmation test panel and customizable test panels include extensive subcategories to detect prescription drugs for pain management; depression, insomnia, anxiety, seizures and panic disorder treatment; mental, psychotic and behavior problem treatment; and for relaxing muscles and relieving pain and discomfort caused by strains, sprains, and other muscle injuries. Aside from prescription drugs, our test analytes also include some illicit drugs. Representing drug categories include opioids, benzodiazepines, antidepressants, stimulants, hypnotic, skeletal muscle relaxants, antipsychotics, illicit drugs and harder-to-detect designer drugs:

Alkaloids

Cotinine‍

Anticonvulsants‍

Gabapetin (Gralise, Gabarone, Neurontin)

Pregabalin (Lyrica)‍

Antidepressants, Serotonergic‍

Fluoxetine (Prozac)

Paroxetine (Paxil)

Sertraline (Zoloft)

Citalopram (Celexa)‍

Antidepressants, Tricyclics‍

Amitriptyline (Amitrip, Elavil)

Desipramine (Norpramin)

Doxepin (Silenor, SINEquan, Zonalon)

Imipramine (Tofranil, Tofranil-PM)

Nortriptyline (Aventyl, Pamelor)‍

Antidepressants, NOS‍

Duloxetine (Cymbalta, Drizalma Sprinkle, Irenka)

Venlafaxine (Effexor)‍

Antipsychotics‍

Clozapine (Clozaril, FazaClo, Versacloz)

Haloperidol (Haldol, Peridol)

Quetiapine (Seroquel)

Risperidone (Risperidal M-Tab, RisperiDONE M-Tab)‍

Benzodiazepines‍

Alprazolam (Niravam, Xanax)

Clonazepam* (KlonoPIN)

Diazepam* (Valium)

Flunitrazepam* (Rohypnol)

Flurazepam* (Dalmane)

Lorazepam (Ativan,
Loreev XR)

Midazolam (Versed)

Nordiazepam (Nordaz, Stilny)

Oxazepam (Serax)

Temazepam (Restoril)‍

Cocaine Metabolite‍

Benzoylecgonine

Fentanyl (Subsys)‍

Norfentanyl‍

Heroin Metabolite‍

6-MAM‍

Ketamine‍

Norketamine‍

Marijuana (THC)‍

THC-COOH (Marinol)‍

Methadone (Methadose)‍

EDDP‍

Meprobamate (Equanil, Miltown)

Other Opioids/Opioid Agonists‍

Buprenorphine (Subutex)

Codeine (Tylenol 2, 3, 4)

Hydrocodone (Norco, Vicodin, Lortab)

Hydromorphone (Dilaudid, Exalgo)

Morphine (Astramorph, Oramorph)

Meperidine (Demerol, Meperitab)

Naloxone (Evzio, Narcan)

Oxycodone (Oxycontin)

Oxymorphone (Opana)

Tapentadol (Nucynta)

Tramadol (Ultram)‍

Sedative Hypotics (Non-Benzodazepine)‍

Zaleplon (Sonata)

Zolpidem (Ambien)‍

Skeletal Muscle Relaxants‍

Carisoprodol (Soma)

Cyclobenzaprine (Amrix, Flexeril)‍

Stimulants‍

Amphetamine (Addreal)

Methamphetamine (Desoxyn)

MDMA (Ecstasy)

MDA (Similar to MDMA)

Methylphenidate (Ritalin) Ritalinic acid

Phencyclidine (PCP, Angel Dust)

* Metabolite of corresponding parent drug is tested.

‍

Startling Statistics

63% of Americans taking prescription drugs strayed from their physician’s treatment plan and three in five were taking medications that weren’t prescribed, according to a Stanford Medicine study. Nearly one-third has stopped taking a prescribed drug without talking to their healthcare provider, according to an NPR poll. Further, a review in the Annals of Internal Medicine revealed that 20-30% of prescriptions are never filled and nearly 50% of chronic disease medications are not taken as prescribed.
Opioid addiction steals 54,600 American lives every year, and deaths associated with drug overdose, including prescription opioids and illicit drugs, have increased twofold in a decade. In addition to the unnecessary loss of life, opioid misuse is threatening the future of the physicians writing opioid prescriptions.
Opioids – prescription opioids, heroin and synthetic opioids – are involved in two of every three drug overdose deaths, underlining the importance of regular prescription drug monitoring.

Important Legal Protection for Physicians

Our toxicology testing, extensive monitoring and chronic pain management care solutions provide critical information to your medical practice to follow federal compliance standards, regulations that require regular patient follow-up testing, and retractable pain laws and guidelines, which vary by state, to protect physicians who legitimately prescribing opioids to patients needing chronic pain management.

General Health Testing Services

Women's Health Panel

The ABC's of Vaginal Health:

Aerobic Vaginitis (AV)

Group B Streptococcus (GBS)
Staphylococcus aureus
Escherichia coli
Enterococcus faecalis

Bacterial Vaginosis (BV)

Atopobium vaginae
Bacterial Vaginosis Associated Bacterium 2 (BVAB2)
Gardnerella vaginalis
Megasphaera species (Type 1 and Type 2)
Lactobacillus Profiling by qPCR

Considered Medically Necessary by the CDC and Aetna for the Management of Vaginitis and the Diagnosis of Bacterial Vaginosis in Symptomatic Women1, 2

Candida Vaginitis (CV)

Candida albicans
Candida glabrata
Candida krusei
Candida parapsilosis
Candida tropicalis

Diagnostic Advantages

One vial, multiple pathogens
DNA amplification via PCR technology
Microbial drug resistance profiling
High precision robotic accuracy
High diagnostic sensitivity & specificity
Specimen viability up to 5 days after collection
Test additions available up to 30 days after collection
No refrigeration required before or after collection
Blood and excess mucus will not affect results

AV IS NOT BV

A Comparison of Bacterial Vaginosis and Aerobic Vaginitis

Urinalysis

Women's Health Panel

We offer comprehensive urinalysis, using advanced technology to detect potential health issues from urine samples.

At MTSC, we carefully examine the patient’s urine sample visually (turbidity, color, foam, and odor to identify pathological conditions, such as blood in urine or protein level) and microscopically (to identify microbiological presence, red blood cells, white blood cells, urinary crystals, or sperm).

In addition, we perform chemical dipstick tests to identify pH, bilirubin (product of RBCs), specific gravity, glucose, ketones, leukocyte esterase (product of WBCs), nitrites, and protein. The dipstick changes color when exposed to certain substances in the urine.

It is recommended to consult a doctor if you notice changes in urine color or odor, pain during urination, abdominal pain, or urinary tract infections. Using state-of-the-art modern machines like Siemens Clinitek Status, the urinalysis test is offered to all ages, including children.

Blood Wellness Testing

Gain a comprehensive understanding of the patient's overall health.

MTSC’s comprehensive Blood Wellness panel provides vital insight into a patient’s overall health and is instrumental in developing a patient-centered wellness plan. Our extensive panel also can detect health issues before they become chronic or life-threatening.

Complete Blood Count (CBC)

Detects quantitative disorders of RBC, Leukocytes (differential) and platelets

Diabetes Panel

Includes serum glucose concentration, HbA1c and microalbuminuria tests

Blood Wellness Panel

Liver and kidney enzymes to assess liver and kidney functions and blood protein levels
Hormones
- balanced hormones for overall male and female wellness
- sex hormones for male and female fertility
Prostate-specific Antigen (PSA) to screen for prostate cancer
Thyroid enzymes for hyperthyroidism and hypothyroidism screening
Vitamins, nutrients and iron, including Vitamin B-12 and Vitamin B-9 (folate), for healthy blood assessment and anemia testing

Additionally, urine is tested for kidney function, bacteria within the ureter and
urinary tract health.

Value-based Healthcare

The trend toward value-based care is gaining momentum. Forward-thinking physicians recognize Blood Wellness testing as an opportunity to be rewarded for improving their quality of patient care and reducing the effects and incidences of chronic diseases based on metrics such as reducing hospital readmissions, boosting preventative care and utilizing certified health technologies.

Hematology

Women's Health Panel

Hematology

Hematology tests help diagnose anemia, blood cancers, infection, and inflammatory conditions/diseases.

MTSC Medical Technologists examine patients’ blood using automated blood analyzers (Abbot Cell-DYN Ruby) and Trained Hematologists verify it using blood smears.

Hematology tests include 3 types of blood cells: RBCs, WBCs, and Platelets, including RBC indices (hematocrit, MCV, Hemoglobin, MCH, MCHC), differential WBC count, prothrombin time, activated partial thromboplastin time, and INR.

Our automated hematology analyzer provides rapid results that assist Physicians in diagnosing blood disorders and malignancies including types of hemophilia, leukemia, lymphoma, and sickle-cell anemia.

Clinical Chemistry And Immunochemistry

The various laboratories that we work with offer a range of clinical chemistry test panels for different body fluids for diagnostic and therapeutic purposes.

Using Roche Cobas 6000 platform (chemistry: c501), our Medical Technologists can analyze hundreds of samples and report results accurately with fast turnaround times, and can help diagnose issues such as kidney and liver disorders, cardiac function, glucose levels, minerals, vitamins, and electrolytes.

With the Roche Cobas 600 platform (immunochemistry: e-601), GenviewDX can perform immunoassays to measure the presence or concentration of antibodies or antigens in a solution using an antigen or an antibody as a probe.

We use high-sensitive electro-chemiluminescence reporter assays, which can help detect small amounts of analyte present in a sample. Some examples of these tests include hepatitis B; HIV-antibody and HIV-p24 antigen; CEA and hormones included in the thyroid panel; PSA; and infectious diseases such as syphilis.

Revolutionizing Medical Testing Providing personalized medic

Vision

Mission

Our vision is to bring medical testing into the future by leveraging Next-Generation Sequencing Technology, delivering a personalized medicine experience to patients, and providing doctors with data they need to make an informed treatment decision.

Mission

Our mission is to revolutionize medical testing for doctors and patients through Next-Generation Sequencing, focusing on exceptional customer service, unparalleled accuracy, and swift turnaround times.

We Are The Future in preventive healthcare

Focused on the future with PCR technology

Through our robust reporting capabilities, we are revolutionizing personalized medicine for both patients and doctors. The data we collect is used to improve treatment for patients of the future.

Offering best-in-class turnaround time, we give doctors test results for each individual patient on a case-by-case basis. In turn, patients get answers faster and doctors can be confident in the treatment plan they are providing.

Our goal is to help both doctors and patients make important health decisions through the delivery of expedited, accurate, and data-backed testing services, while safeguarding quality and accuracy.

We don’t just provide test results. Through research, we are taking the patient and doctor experience into the future.